Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry
Zanfina Ademi, Christopher M Reid, Bruce Hollingsworth, Johannes Stoelwinder, Ph Gabriel Steg, Deepak L Bhatt, Margarite Vale, Danny Liew
CLINICAL THERAPEUTICS | ELSEVIER | Published : 2011
BACKGROUND: Although few cardiovascular registries report the costs of illness or cost-effectiveness of health interventions, such information is critical to inform the effective and cost-effective management of cardiovascular disease, particularly if drawn from population-based registries, which more accurately reflect clinical practice and follow up patients for much longer than clinical trials. OBJECTIVE: The goal of this study was to estimate the cost-effectiveness of closing the statin "treatment gap" in the secondary prevention of coronary artery disease (CAD) in Australia. METHODS: A decision analysis Markov model was developed with yearly cycles and the health states of alive or dead..View full abstract
Awarded by Australian Research Council
This work was supported by Monash University. In addition, it was supported in part by the Australian Research Council Linkage Project LP077532. The international REACH registry is sponsored by sanofi-aventis, Bristol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan) and is endorsed by the World Heart Federation. The REACH registry enforces a no-ghost-writing policy. A complete list of the REACH Registry Investigators appears in JAMA (2006;295:180-189).